11th Nov 2014 16:42
Skyepharma to present at two forthcoming investor conferences
LONDON, UK, 11 November, 2014 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that its senior management will present at the Stifel Healthcare Conference 2014 in New York and the Jefferies 2014 Global Healthcare Conference in London next week.
Skyepharma's Chief Financial Officer, Andrew Derodra, will present at the Stifel Healthcare Conference 2014 in New York on Wednesday, 19 November, 2014 at 4:10 p.m. Eastern Time (ET), 9:10 p.m. GMT.
The Company's Chief Executive Officer, Peter Grant, will present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, 20 November, 2014 at 12:20 p.m. GMT.
Copies of the presentations will be available on the Investor Relations section of the Skyepharma website at http://www.skyepharma.com/Investors/Presentations_and_webcasts/Default.aspx?id=25
-Ends-
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 (0)7860 361746 |
N+1 Singer | |
Shaun Dobson/Gillian Martin | +44 (0)20 7496 3000 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L